CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Lopinavir/Ritonavir 400 mg/100 mgWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug2092 Ribavirin Wiki 0.71
drug1220 Interferon Beta-1B Wiki 0.58
drug1372 Lopinavir/ritonavir Wiki 0.32
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19

Blinded, multicenter, placebo-controlled, randomized clinical trial evaluating lopinavir/ritonavir vs placebo in early outpatient treatment of adults with COVID-19

NCT04372628 COVID-19 Drug: Lopinavir/Ritonavir 400 mg/100 mg Other: Placebo

Primary Outcomes

Description: Death Hospitalized on mechanical ventilation or extracorporeal membrane oxygenator (ECMO) Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with symptoms and limitation in activity Not hospitalized with symptoms but with no limitation in activity Not hospitalized without symptoms nor limitation in activity symptoms at the milder end of the scale for this outpatient trial

Measure: Modified COVID Ordinal Outcomes Scale: Study Day 15

Time: Day 15

Secondary Outcomes

Description: Death Hospitalized on mechanical ventilation or ECMO Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with symptoms and limitation in activity Not hospitalized with symptoms but with no limitation in activity Not hospitalized without symptoms nor limitation in activity

Measure: Modified COVID Ordinal Outcome Scale: Study Day 8

Time: Day 8

Description: Death Hospitalized on mechanical ventilation or ECMO Hospitalized on supplemental oxygen Hospitalized not on supplemental oxygen Not hospitalized with symptoms and limitation in activity Not hospitalized with symptoms but with no limitation in activity Not hospitalized without symptoms nor limitation in activity Ordinal Scale

Measure: Modified COVID Ordinal Outcome Scale: Study Day 29

Time: Day 29

Description: Proportion hospitalized

Measure: Proportion of patients hospitalized: Day 1 to 29

Time: Day 1 to Day 29

Description: Number of days from enrollment to hospitalization

Measure: Time to hospitalization Day 1 to Day 29

Time: Day 1 to Day 29

Description: Number of days from enrollment to resolution of COVID-19 symptoms

Measure: Time to symptom resolution: Day 1 to Day 29

Time: Day 1 to Day 29

Description: Survival status

Measure: All-cause, all-location mortality: Day 1 to Day 29

Time: Day 1 to Day 29

Description: Number of Days without oxygen

Measure: Oxygen-free days: Day 1 to Day 29

Time: Day 1 to Day 29

Description: Number of days without fever

Measure: Fever-free days: Day 1 to Day 29

Time: Day 1 to Day 29

Description: Number of days without ventilator use

Measure: Ventilator-free days: Day 1 to Day 29

Time: Day 1 to Day 29

Description: Number of days outside the ICU

Measure: ICU-free days: Day 1 to Day 29

Time: Day 1 to Day 29

Description: Number of days outside the hospital

Measure: Hospital-free days: Day 1 to Day 29

Time: Day 1 to Day 29


No related HPO nodes (Using clinical trials)